YOLFTbeta
68

Jiangsu Bioperfectus Technologies Co Ltd

688399 · SHG · Healthcare / Biotechnology

22.26CNY-0.83 (-3.59%)

Price History

Full chart

Market Stats

Previous Close23.09
Open23.69
Day Range22.00 – 23.69
52-Week Range23.24 – 94.00
Volume1.56M
Market Cap3.42B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.20
Dividend Yield0.00%
Beta0.76
50-Day Avg27.39
200-Day Avg37.31

About

Jiangsu Bioperfectus Technologies Co., Ltd., a molecular diagnostic company, engages in the research, development, production, and sale of in vitro diagnostic products in China. The company offers in vitro diagnostic reagents and supporting testing equipment, as well as in vitro testing services. It also provides HPV and cervical cancer testing services, respiratory infection detection solution, solutions for infectious diarrhea, and STI detection solution for reproductive tract infections. In addition, the company offers biological technology platforms, including nucleic acid detection platforms, NGS technology platforms, POCT technology platforms, mass spectrometry technology platforms, and automated control and detection platforms. Jiangsu Bioperfectus Technologies Co., Ltd. was founded in 2010 and is headquartered in Taizhou, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Guoqiang Wang
  • Employees578
  • HeadquartersNo. 837 Yaocheng Avenue, Taizhou, China, 225300, China
  • Websitehttps://www.s-sbio.com

Leadership

  • Dr. Guoqiang WangChairman & GM · b. 1970
  • Ms. Yuanyuan MengFinancial Director · b. 1984
  • Ms. Yuanyuan HuDeputy GM, Secretary & Director · b. 1986
  • Mr. Guohui ZhouDeputy General Manager · b. 1973
  • Mr. Haidong ShenDeputy General Manager of R&D Center · b. 1970

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue129.14M187.29M230.70M288.79M1.74B2.84B5.53B403.18M349.61M340.38M
Growth (%)-+45.02%+23.18%+25.18%+502.39%+63.19%+94.95%-92.72%-13.29%-2.64%
Cost of Revenue23.83M32.64M41.96M52.70M390.72M879.96M2.38B253.94M147.64M124.92M
Gross Profit105.31M154.64M188.74M236.09M1.35B1.96B3.15B149.24M201.97M340.38M
Gross Margin81.55%82.57%81.81%81.75%77.54%69.00%57.00%37.02%57.77%100.00%
Operating Expense96.95M104.08M115.45M141.05M385.95M564.16M1.00B514.30M193.16M371.27M
Operating Income8.36M50.56M73.29M95.04M963.01M1.39B2.15B-365.06M8.81M-30.89M
Operating Margin6.47%27.00%31.77%32.91%55.36%49.13%38.84%-90.54%2.52%-9.08%
EBITDA19.24M60.05M86.91M112.15M983.31M1.43B2.23B-299.81M61.29M17.75M
EBITDA Margin14.90%32.06%37.67%38.83%56.52%50.36%40.25%-74.36%17.53%5.21%
Net Income8.36M42.67M63.82M83.76M819.57M1.19B1.83B-373.81M-2.00M-39.71M
Net Income Margin6.47%22.78%27.67%29.00%47.11%42.03%33.03%-92.72%-0.57%-11.67%
R&D14.63M21.73M26.38M38.56M72.07M106.64M185.82M135.53M101.23M78.72M
R&D as % of Total Revenue11.33%11.60%11.44%13.35%4.14%3.76%3.36%33.62%28.95%23.13%
Interest Expense0068.52K83.47K236.85K4.23M5.83M7.08M7.75M8.53M
Interest Expense % of Total Revenue0.00%0.00%0.03%0.03%0.01%0.15%0.11%1.76%2.22%2.51%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets285.99M310.64M395.56M1.15B2.28B3.50B4.89B3.91B3.74B3.55B
Total Liabilities34.09M50.37M71.46M133.57M613.18M962.89M1.11B501.31M489.32M625.71M
Total Equity251.90M260.28M324.10M1.02B1.66B2.54B3.78B3.41B3.25B2.93B
Cash12.40M21.72M212.14M248.69M1.14B1.29B1.79B1.77B810.63M483.77M
Total Debt186.40K151.30K65.80K177.44K50.05M164.23M103.79M165.64M234.91M-
Net Debt-12.22M-21.57M-212.07M-248.51M-1.09B-1.12B-1.69B-1.60B-575.72M-

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow22.09M61.59M85.82M106.72M935.88M985.52M1.96B-113.14M145.93M30.34M
Investing Cash Flow-190.71M-17.98M-75.41M-654.42M-259.60M-748.63M-717.89M462.35M-873.01M-
Financing Cash Flow98.39M-34.29M612.93M612.93M-125.89M-234.00M-667.43M55.26M-94.76M-
Capital Expenditure22.37M29.31M98.74M105.77M134.56M303.62M350.74M111.34M62.86M64.45M
Free Cash Flow-279.28K32.29M-12.92M944.27K801.32M681.91M1.61B-224.48M83.06M-34.11M
Dividends Paid3.89M34.29M175.89M175.89M175.86M322.41M586.20M6.04M7.08M293.07M
FCF to OCF-1.26%52.42%-15.06%0.88%85.62%69.19%82.15%198.41%56.92%-112.43%
Dividend Paid to FCF-1393.36%106.21%-1361.40%18627.47%21.95%47.28%36.32%-2.69%8.52%-859.14%

Earnings

Report DateDec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Mar 25, 2021Apr 28, 2021Aug 26, 2021Oct 29, 2021Mar 25, 2022Apr 28, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023
EPS Estimate--------------
EPS Actual0.581.773.484.684.066.611.968.433.3610.7710.286.673.47-0.33
Surprise--------------
Timing--------Pre-marketPre-market----

Key Statistics & Ratios

Market Cap3.42B
Enterprise Value2.30B
Trailing P/E0.00
Forward P/E0.00
Price / Sales11.00
Price / Book1.18
EPS-0.20
Book Value23.71
Revenue (TTM)310.89M
Gross Profit (TTM)178.68M
EBITDA-11.12M
Profit Margin-8.20%
Operating Margin-19.58%
Return on Equity-0.82%
Return on Assets-0.97%
Shares Outstanding124.13M
Shares Float63.12M
Beta0.76
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20221×
10.00May 30, 2022
20211×
5.50Jun 23, 2021
20202×
1.50Sep 25, 20201.50Jun 22, 2020